High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin - A CALGB 59804 correlative study.
Publication
, Conference
Lai, R; Hsi, ED; Mackey, J; Jung, S; Johnson, JL; Cook, JR; Jones, D; Said, JW; Cheson, BD; Bartlett, NL
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
442S / 442S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lai, R., Hsi, E. D., Mackey, J., Jung, S., Johnson, J. L., Cook, J. R., … Bartlett, N. L. (2006). High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin - A CALGB 59804 correlative study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 442S-442S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Lai, R., E. D. Hsi, J. Mackey, S. Jung, J. L. Johnson, J. R. Cook, D. Jones, J. W. Said, B. D. Cheson, and N. L. Bartlett. “High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin - A CALGB 59804 correlative study.” In JOURNAL OF CLINICAL ONCOLOGY, 24:442S-442S. AMER SOC CLINICAL ONCOLOGY, 2006.
Lai R, Hsi ED, Mackey J, Jung S, Johnson JL, Cook JR, et al. High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin - A CALGB 59804 correlative study. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 442S-442S.
Lai, R., et al. “High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin - A CALGB 59804 correlative study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 442S-442S.
Lai R, Hsi ED, Mackey J, Jung S, Johnson JL, Cook JR, Jones D, Said JW, Cheson BD, Bartlett NL. High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin - A CALGB 59804 correlative study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 442S-442S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
442S / 442S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences